
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) – Research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Enliven Therapeutics in a research report issued on Friday, November 13th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($1.62) for the year, up from their previous forecast of ($1.74). HC Wainwright currently has a “Buy” rating and a $73.00 price target on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q4 2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.46) EPS, Q4 2027 earnings at ($0.48) EPS and FY2027 earnings at ($1.80) EPS.
A number of other research firms also recently issued reports on ELVN. William Blair started coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating for the company. Mizuho raised their price objective on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Morgan Stanley began coverage on Enliven Therapeutics in a research report on Friday, October 2nd. They set an “overweight” rating and a $70.00 price objective on the stock. Barclays started coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 target price on the stock. Finally, Guggenheim reissued a “buy” rating and issued a $78.00 target price on shares of Enliven Therapeutics in a research report on Friday, November 6th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Enliven Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $75.44.
Read Our Latest Stock Analysis on ELVN
Enliven Therapeutics Stock Down 2.4%
Shares of ELVN opened at $47.62 on Tuesday. The firm’s 50-day moving average price is $46.20 and its 200-day moving average price is $43.78. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $62.32.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09.
Hedge Funds Weigh In On Enliven Therapeutics
Several large investors have recently made changes to their positions in ELVN. Aquatic Capital Management LLC boosted its position in shares of Enliven Therapeutics by 51.5% in the 3rd quarter. Aquatic Capital Management LLC now owns 12,730 shares of the company’s stock worth $584,000 after purchasing an additional 4,330 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Enliven Therapeutics by 3.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 333,292 shares of the company’s stock worth $15,278,000 after buying an additional 11,136 shares during the last quarter. Entropy Technologies LP bought a new position in Enliven Therapeutics during the 3rd quarter valued at approximately $256,000. Jump Financial LLC bought a new position in Enliven Therapeutics during the 3rd quarter valued at approximately $333,000. Finally, Marshall Wace LLP increased its position in Enliven Therapeutics by 117.1% during the 3rd quarter. Marshall Wace LLP now owns 1,155,392 shares of the company’s stock valued at $52,963,000 after buying an additional 623,123 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In related news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the transaction, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at $1,462,240. This trade represents a 13.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $46.67, for a total transaction of $606,710.00. Following the sale, the director directly owned 13,000 shares in the company, valued at $606,710. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 25,036 shares of company stock valued at $1,141,289. 3.00% of the stock is owned by company insiders.
Enliven Therapeutics Company Profile
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.
Featured Articles
- Five stocks we like better than Enliven Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
